Visual Universitätsmedizin Mainz

Home Treatment of Patients with Low-Risk Pulmonary Embolism With the Oral Factor Xa Inhibitor Rivaroxaban (HoT-PE)

  • Head of study: Professor Stavros Konstantinides, MD
  • EudraCT No.: 2013-001657-28

The present study, “Home Treatment of Pulmonary Embolism” (HoT-PE), is a prospective, multicenter, single-arm phase 4 management (cohort) trial which will determine whether early discharge and out-of-hospital treatment of patients with low-risk acute PE (as defined by standardized inclusion and exclusion criteria) with the new oral factor Xa inhibitor rivaroxaban is feasible, effective and safe. In patients clinically suspected of having acute PE, confirmation of the diagnosis and screening for inclusion/exclusion criteria will be completed within 48 hours of admission. Patients will be enrolled after providing written informed consent.

Further information about HoT-PE (Pdf-file, 207,2 KB)

Study Type


Study Design

Single-arm phase IV management (cohort) trial

Official Title

Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial


Recruiting completed

Steering Committee

Stavros Konstantinides, Mainz, Harald Binder, Mainz, Christine Espinola-Klein, Mainz, Mareike Lankeit, Mainz, Philipp Wild, Mainz, Rupert Bauersachs, Darmstadt, Christoph Bode, Freiburg, Annette Geibel, Freiburg, Michael Pfeifer, Donaustauf, Sebastian Schellong, Dresden